𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Androgen regulation of the human pseudoautosomal gene MIC2, a potential marker for prostate cancer

✍ Scribed by Jiancheng Shen; Haiyen E. Zhau; Stephen D. Hursting; Leland W. K. Chung


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
560 KB
Volume
23
Category
Article
ISSN
0899-1987

No coin nor oath required. For personal study only.

✦ Synopsis


Using the differential display-polymerase chain reaction technique to identify androgen-responsive genes in the human prostatic tumor cell line LNCaP, we cloned an expression tag homologous to the human pseudoautosomal gene MIC2. The role of MIC2 in the prostate had not previously been studied. We used a series of cell lines derived from LNCaP that varied in their degree of differentiation and metastatic potential to assess the relationship between MIC2 expression and androgen responsiveness in prostate cancer. The expression of MIC2 mRNA and its product E2 was upregulated by androgen in a dose-and time-dependent manner in the parental LNCaP line and correlated with the expression of prostate-specific antigen. In the LNCaP sublines and an androgen-repressed invasive human prostate cancer cell line (ARCaP), MIC2 gene expression was not regulated by androgen and was associated with poorer differentiation, decreased androgen sensitivity, and higher metastatic potential. Immunohistochemical analyses indicated that E2 was expressed in tissues from patients with primary prostate cancer (16 of 20), in fetal prostatic tissues (low levels in all 10 fetal tissues assessed), and sporadically in benign prostatic hyperplasia tissues (one of four). The normal prostate tissues did not show positive E2 staining, with the exception of one central-zone section from one of the eight normal prostate samples assessed. These findings suggest that deregulation of expression of the human pseudoautosomal gene MIC2 occurred in the prostate.


πŸ“œ SIMILAR VOLUMES


Expression of the human mismatch repair
✍ Fredrick S. Leach; Jer-Tsong Hsieh; Kyle Molberg; M. Hossein Saboorian; John D. πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 224 KB πŸ‘ 2 views

## Background: The human mismatch repair (mmr) gene hmsh2 (human muts homolog-2) is a dna repair gene that has been reported to be mutated in 40% of hereditary nonpolyposis colon cancer (hnpcc) kindreds and a small percentage of sporadic tumors. hnpcc is a cancer predisposition syndrome with an inc

Development of a hammerhead ribozyme aga
✍ Dorai, Thambi; Olsson, Carl A.; Katz, Aaron E.; Buttyan, Ralph πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 503 KB

## Background: The bcl-2 oncoprotein suppresses apoptosis and, when overexpressed in prostate cancer cells, makes these cells resistant to a variety of therapeutic agents, including hormonal ablation. therefore, bcl-2 provides a strategic target for the development of gene knockout therapies to tre

Gene-directed enzyme prodrug therapy for
✍ Rosetta Martiniello-Wilks; Allison Dane; Dale J. Voeks; Geetha Jeyakumar; Elin M πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 310 KB πŸ‘ 1 views

## Abstract ## Background Gene‐directed enzyme prodrug therapy (GDEPT) based on the __E. coli__ enzyme purine nucleoside phosphorylase (PNP) represents a new approach for treating slow growing tumours like prostate cancer (PCa). Expressed enzyme converts a systemically administered prodrug, fludar